As per the report published by Fior Markets, the global anthrax vaccines market is expected to grow from USD 432.7 Million in 2018 to USD 879.5 Million by 2026 at a CAGR of 9.3% during the forecast period 2019-2026.       North America is dominating the market owing to government initiatives to prevent the spread of anthrax and the existence of many ongoing programs under organizations like HHS-CDC, BARDA, ASPR, NIAID, and the FDA which are stimulating the growth of the market.


Anthrax Vaccines Market by Vaccine Type (Live Vaccines, Cell free PA Vaccines), Distribution Channel, Application Region Global Industry Analysis, Market Distribution Channel, Share, Growth, Trends, and Forecast 2019to 2026.

Leading companies in the industry include Emergent BioSolutions, Merial, Merck, Zoetis , Bayer Sanidad Animal, Colorado Serum, PharmAthene, Tiankang, Biogénesis-Bago, CAVAC, Rosenbusch, Agrovet, Vecol, CVCRI, IVPM, Prondil, CDV, Indian Immunologicals, Botswana Vaccine Institute, Ceva Santé Animale, Intervac, JOVAC, and among others.In order to their enhance market position, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership.For instance, in March 2019, Emergent BioSolutions Inc., a significant player in the market announced that it has started a phase III study to assess AV7909 for the post-exposure prevention of anthrax disease. The phase III program will determine the lot immunogenicity, consistency, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) after a two-dose schedule, administered intramuscularly in healthy adult patients.

The vaccine type segment is classified as live vaccines and cell free PA vaccines. The live vaccines segment is growing with the highest CAGR of 11.6% over the forecast period. Live vaccine contains spores from attenuated strains of Bacillus anthrac is that are used to treat anthrax disease.Anthrax is caused by a large bacterium and risk of inhalation infection is the main indication for anthrax vaccination.  All animal vaccines are live vaccines, and their use requires a withholding period prior to slaughter for human consumption. This period may be stipulated on the label of the vaccine or in the accompanying leaflet, and varies from 3 to 6 weeks.Anthrax vaccines, being living organisms, are restricted to veterinary use in some countries, and in some jurisdictions they can only be used with the approval of the official veterinary service.The distribution channel segment is divided into segments such as hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment is dominating the market and valued around USD 220.24 Million in 2018. The anthrax vaccines are mostly sold in hospital pharmacies. Anthrax vaccines are not contagious from person to person, however, standard hospital practices of hygiene are need to follow for the treatment that can be only given in the hospitals.Application segment includes human use and animal use. Animal use segment is dominating the market with the highest share of 61.50% in 2018. High proportion of anthrax vaccines are used for animal. Anthrax is primarily a disease of herbivores. A live unencapsu-lated variant of B. anthrac is and strain stern has been used in veterinary practice to protect livestock. People can get anthrax from contact with infected animals, wool, meat, orhides. In its most common form, anthrax is a skin disease that causes skin ulcers and usually fever and fatigue. Up to 20% of these cases are fatal if untreated. Hence this has increased the animal use segment growth. 


Anthrax is defined as a serious disease which may impact both animals and humans. It is caused by bacteria called Bacillus anthrac is. Growing instances of the disease is one of the driving force. Also, increased eating of under cooked or raw meat from infected animals and rising need of personalized medicines are another two factors fuelling the growth of market.But low rate of voluntary screening for the anthrax disease is restricting the growth of anthrax vaccines market. However,the cost-effectiveness of immunizations, new investments opportunities from government, research foundations, donors, advances in research and manufacturing technologies is anticipated to fuel the market growth in the forthcoming years.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs.